KLUS Pharma is Attending BIO-Europe Spring

KLUS Pharma will attend BIO-Europe Spring from March 22-25. As a subsidiary of Kelun-Biotech, we expect to introduce and provide updates for several of our innovative small molecules and biologics. Our main focus is developing immunotherapies and targeted therapies to treat cancer, with other ongoing projects targeting HBV, NASH, autoimmune disease, and clotting disorders.

We are actively looking for potential partners with strong clinical and commercialization teams to further develop these products. We are excited to connect with potential partners during the upcoming BIO-Europe Spring virtual event and welcome interested parties to reach out via the contact form on our website.

Our company is also looking to partner on external projects or technologies related to the discovery or development of innovative biotherapeutics for cancer. Our interests may include the following:
-Antibody-Drug Conjugate (ADC) technologies and inventions
-Therapeutic bispecific antibodies or technologies
-First-in-class targets for oncology, especially in the tumor microenvironment
-Fc function enhancement technologies such as ADCC, ADCP, and CDC
-Off-the-shelf cell therapies with potential to treat solid tumors
-First-in-class or best-in-class small molecules with preliminary efficacy data